Blockchain Registration Transaction Record

NanoViricides' NV-387 Shows 130% Survival Boost Against Measles

NanoViricides' NV-387 drug candidate shows 130% survival improvement against Measles in animal studies. No approved Measles treatment exists, making this potential first-in-class therapy groundbreaking.

This development represents a potential breakthrough in treating Measles, a highly contagious disease that continues to cause outbreaks worldwide despite available vaccines. The absence of any approved therapeutic for Measles means infected individuals currently receive only supportive care, with severe cases risking pneumonia, encephalitis, and death. NV-387's demonstrated ability to not only suppress the virus but also reduce inflammation-induced lung damage addresses two critical aspects of Measles pathology. For populations with limited vaccine access, immunocompromised individuals, or those who cannot receive vaccines, an effective treatment could significantly reduce mortality and long-term complications. Furthermore, the broad-spectrum potential of NV-387 against multiple respiratory viruses suggests this technology platform could transform how we approach viral outbreaks more broadly, providing crucial tools for future pandemic preparedness.